Immunic, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed February 22, 2024. This is an annual report, not a standalone Q4 report. Immunic is a clinical-stage biotechnology company with no approved products or product-sales revenue.
Business context and pipeline
- Vidofludimus calcium (IMU-838): Phase 3 ENSURE trials for relapsing multiple sclerosis (RMS) and Phase 2 CALLIPER for progressive MS (PMS). CALLIPER enrolled 467 patients; full topline data are expected in April 2025. An ENSURE interim futility analysis is expected in late 2024, with the first trial readout expected in Q2 2026.
- IMU-856: Preparing a Phase 2 trial in active celiac disease despite a gluten-free diet, following reported positive Phase 1b results. The candidate targets intestinal barrier function.
- IMU-381: Selected as a next-generation gastrointestinal development candidate; remains preclinical.
- Immunic deprioritized clinical development of izumerogant (IMU-935) in psoriasis and castration-resistant prostate cancer in April 2023 to focus resources on other programs.
Financial results and liquidity
| Metric (USD millions, except per-share) | FY2023 | FY2022 | Change |
|---|---|---|---|
| Product revenue | None | None | No commercial sales |
| Research and development expense | 83.2 | 71.3 | +17% |
| General and administrative expense | 16.0 | 15.3 | +5% |
| Total operating expenses | 99.2 | 119.5 | -17% |
| Operating loss | (99.2) | (119.5) | Loss narrowed |
| Net loss | (93.6) | (120.4) | Loss narrowed 22% |
| Net loss per share, basic and diluted | (2.11) | (3.78) | |
| Cash used in operating activities | (70.8) | (65.1) | Use increased |
- Net loss improved primarily because FY2022 included a $33.0 million non-cash goodwill impairment; higher R&D spending in 2023 reflected advancing MS trials and IMU-856 work. Interest income and other income also improved.
- Cash and cash equivalents were $46.7 million at year-end, versus $106.7 million a year earlier; 2022 also had $9.6 million of time-deposit investments, which were sold in 2023. Total assets were $54.3 million and total liabilities $25.4 million at December 31, 2023. No funded debt is reported; liabilities include operating leases.
- Working capital was approximately $27.8 million (current assets $52.5 million less current liabilities $24.7 million). FY2023 investing activities provided $9.5 million, mainly from time deposits sold; financing activities provided $1.0 million.
- On January 8, 2024, the company closed the first tranche of a private placement for $80 million gross and approximately $75 million net. Management states the proceeds are expected to fund operations beyond 12 months from the financial statement issuance date. Separately, the filing says year-end cash alone was expected to fund operations into Q3 2025; runway depends on assumptions and further financing may be needed.
Margins are not meaningful for this pre-revenue company. The filing reports no product-sales revenue and continuing losses; therefore profitability and conventional operating margins are not established.
Material changes, outlook and risks
- R&D expense rose $12.0 million, mainly from higher external costs for ENSURE and CALLIPER, vidofludimus calcium drug supply, personnel and IMU-856. These increases were partly offset by lower izumerogant and UC trial costs.
- The January 2024 private placement provides for up to $240 million gross in three tranches. The second $80 million tranche depends on CALLIPER topline data and specified stock-price and trading-volume conditions; the third tranche has similar conditions and may be funded cashlessly, reducing cash proceeds. The first tranche is closed; later proceeds are not assured.
- Principal risks include clinical-trial failure or delay, regulatory approval uncertainty, ongoing financing needs and potential dilution, reliance on third-party manufacturers and CROs, competition, and foreign-exchange exposure. The company cites disruptions and increased costs from the war in Ukraine; Ukraine is expected to account for about 20% of ENSURE enrollment.
- CALLIPER interim results showed a 6.7% reduction in serum NfL at 24 weeks versus a 15.8% increase on placebo (N=203; p=0.01, post hoc); these are interim biomarker findings, not confirmatory clinical outcome data. IMU-856 Phase 1b findings were reported as positive and well tolerated. CALDOSE-1 UC induction failed its primary endpoint, although exploratory maintenance analyses showed positive findings; the company says it does not plan further UC development without a partner.
- Management expects significant expenses and losses for the foreseeable future. It is evaluating strategic collaborations and stage-appropriate pre-commercial activities. No product-approval or revenue guidance is provided.
- Two U.S. patent applications for vidofludimus calcium dosing/treatment received notices of allowance, with expected protection into 2038 and 2041, respectively, subject to applicable conditions.
- Auditor Baker Tilly issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor was not engaged to opine on internal-control effectiveness. No material litigation was reported.
Most important facts for investors to verify
- Cash runway assumptions and the actual net proceeds received from the January 2024 tranche; monitor whether conditional later tranches occur.
- ENSURE interim analysis timing and results, and whether the first Phase 3 readout remains on track for Q2 2026.
- Full CALLIPER topline results expected in April 2025, including clinical endpoints and safety—not only interim biomarkers.
- IMU-856 Phase 2 initiation, design, funding needs and subsequent results; confirm the status of IMU-381 preclinical development.
- Potential dilution and financing capacity: the company proposed increasing authorized common shares from 130 million to 500 million at a March 2024 special meeting; the filing states approval is important to future equity financing.
- Clinical-trial exposure to Ukraine-related disruption, foreign-exchange movements, and the company’s reliance on external trial and manufacturing providers.